What did @karlilynnb1 actually say?
Honestly? Almost nothing, in words. The transcript is song lyrics, not a health claim. But the video does the talking for her: the caption reads "I don't know a life without a double chin… now it's just gone!!!" paired with the #glp1 hashtag. That pairing is the claim. She's attributing a visible change in submental fat, the fat under the chin, to GLP-1 receptor agonist use. She doesn't name a drug, doesn't discuss dosing, and doesn't say how long it took. The message is purely visual and emotional: GLP-1 changed my face. That's a real claim, even if no one said it out loud.
Before-and-after content like this is enormously influential precisely because it feels like proof without requiring any argument. Forty thousand views means forty thousand people who saw a result, not an explanation.
Does the science back this up?
Partially, yes. GLP-1 receptor agonists do reduce overall body fat, and facial and submental fat loss is a documented side effect, though not always a welcome one. The mechanism is systemic, not targeted. You cannot spot-reduce fat with a GLP-1, but when total fat mass drops significantly, the face often changes noticeably.
Semaglutide trials have shown meaningful reductions in body weight. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found a mean 14.9% body weight reduction over 68 weeks in adults with obesity. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 20.9% reduction in the highest-dose group. At those levels of weight loss, facial fat changes are plausible and expected. There is no dedicated randomized trial on submental fat and GLP-1 agents specifically, but the physiology is consistent with what she's showing.
What did they get wrong (or right)?
She didn't get anything factually wrong, because she didn't make a factual statement. That's actually the smarter move from a liability standpoint, but it creates a different problem: implication without accountability. The video implies GLP-1 is the reason for the change, with zero context about diet, exercise, starting weight, duration, or which drug she used. The #workoutmotivation hashtag is also there, which quietly suggests exercise may have played a role, but the #glp1 tag gets top billing in the caption.
What she got right is that visible fat loss around the face and jaw is a real and common outcome for people who lose substantial weight on GLP-1 therapy. That part is supported by the literature. What's missing is that this result is not guaranteed, not fast, and comes with real side effects that no 15-second before-after addresses. Nausea, muscle loss, and what clinicians now call "Ozempic face", meaning hollowed cheeks and accelerated facial aging, are documented concerns (Kahn et al., 2023, JAMA Dermatology).
What should you actually know?
GLP-1 drugs can absolutely change the way your face looks, but the change is a byproduct of systemic fat loss, not a cosmetic feature of the medication. Results vary enormously based on starting body composition, which drug is used, dose titration, and duration of treatment. The double chin disappearing is a realistic outcome for some people who lose 15-20% of their body weight on these agents. It is not a guaranteed outcome, and it is not the same as a cosmetic procedure that targets submental fat specifically.
There is also the issue of facial aging. Rapid fat loss in the face can cause skin laxity and volume loss that some patients find distressing. This is not a reason to avoid GLP-1 therapy if it's clinically indicated, but it is a reason to have a real conversation with a prescriber rather than making decisions based on a TikTok caption.
- GLP-1 therapy requires a licensed prescriber and an appropriate clinical indication.
- Compounded semaglutide is not equivalent to FDA-approved branded formulations.
- Weight loss results in trials are averages across populations, not guarantees for individuals.
The bottom line
This video isn't misinformation. It's an honest personal result shared without context. The danger isn't in what she said. It's in what 39,400 viewers will conclude without ever hearing about side effects, eligibility criteria, or what "gone" actually required in terms of time, drug, and lifestyle. Social proof is powerful, and before-after content on GLP-1 is currently running far ahead of the clinical conversations people need to have before starting treatment.